Before you begin!
📢 The FemTech Observatory Global Survey 2026 is open, and we’re a Community Partner.
If you’re building in women’s health, this is your chance to be counted in the first global, data-driven map of the FemTech ecosystem.
Read to the end for full details on how to participate.
Now to today’s piece.
I recently attended a FemTech accelerator demo day, and the founders genuinely brought their A-game. The pitches were sharp, the problems were real, and the energy in the room was hard not to get excited about.
But it got me thinking.
Beyond the financial projections, the market size slides, and the growth metrics, do investors actually know what a clinically credible women’s health company looks like? Do they know what to look for before endorsing a product that will be used by real women, making real health decisions?
Because clinical credibility in FemTech is easy to perform. It is much harder to actually have. And the companies that have done the real work and the ones that have simply learned the right language can look almost identical at first glance.
Almost.
For investors evaluating women’s health deals, clinical credibility is not a single data point. It is a pattern. And once you know what to look for, it becomes surprisingly readable in how a founder speaks, in what their product claims, and in the decisions they have made along the way.
Here is what separates clinically credible FemTech companies from ones that are simply good at sounding like one.
1. They know exactly what their product is
A clinically credible founder can tell you clearly whether their product is a wellness tool, a medical device, or something that sits in the regulatory space between the two. More importantly, they have thought carefully about what that classification means, for how they market the product, what they can legitimately claim, and what regulatory pathway applies in each market they operate in.
A founder who becomes vague or defensive when you raise this is building on an unstable foundation. Ask directly. The answer will tell you more than the deck will.
2. Their claims and their evidence are proportionate
Ask a clinically credible founder to walk you through the evidence behind their most significant product claim. What you are listening for is not perfection. It is proportionality.
Do they know exactly what their evidence shows and what it does not? Do they distinguish between a small pilot and a peer-reviewed trial? Do they acknowledge what still needs to be validated?
A founder who says “the science is clear” without being able to specify which science is a flag worth noting. Claiming what the data actually supports, and no more, is one of the clearest signals of clinical maturity in an early-stage company.
3. Clinical input has shaped actual product decisions
A medical advisor listed on a website is not the same thing as clinical oversight embedded in product development. Ask directly: What has your clinical advisor actually reviewed? Can you give a specific example of something that changed because of their input?
In a clinically credible company, the answer is specific and recent. The advisor has reviewed health claims before they went live. They have flagged something that needed to change. Where clinical involvement is superficial, the answer tends to be vague. A product that has never been seriously challenged clinically is carrying risks that have simply never surfaced.
4. Their evidence reflects the women they are building for
Clinical credibility is not only about evidence quality. It is about evidence relevance.
A FemTech company building for African women that has validated its product exclusively with users in Europe or North America is carrying a clinical risk its evidence base does not show. Biology, disease burden, care-seeking behaviour, and cultural context all differ. A clinically credible founder knows this and has either built their validation accordingly or is honest about the gap and working to close it.
5. They can tell you what they do not know
This is the most reliable hallmark of all.
A clinically credible founder is not the one with the most polished narrative. It is the one who can clearly articulate the limits of their evidence, the questions their product has not yet answered, and the validation work still ahead.
That honesty, paired with a serious plan for closing the gaps, is what makes a women’s health company worth backing.
The women using these products are making real decisions about their health based on what these tools tell them. That is reason enough to get this right
Better Woman Health works with FemTech founders and investors on clinical strategy and credibility. If you are an investor looking to sharpen your clinical lens or a founder who wants to build a company worth backing, visit ayomide.me to start the conversation.
Better Woman Health is published weekly.
Subscribe at betterwomanhealth.com to get it directly in your inbox.
Your FemTech story deserves to be counted.
The FemTech Observatory Global Survey 2026 is now open, and as a Community Partner, we’re inviting FemTech startups in our network to take part.
This is the first global, bottom-up effort to map the FemTech and women’s health innovation ecosystem using real data from real founders. The more founders who participate, the more accurate and representative that picture becomes, and that picture shapes research, investment, and policy decisions across the ecosystem.
If you’re building in women’s health, your journey matters here.
The survey is short, your data is protected, and the results will be shared publicly to support visibility and ecosystem development.
👉 Request access here: https://tally.so/r/WOe6BQ
⏳ Deadline: June 30th
Let’s make sure our voices are in the room.
Clinical Credibility Toolkit
The Clinical Credibility Toolkit is a free resource designed for FemTech founders building digital tools for women’s health.
It includes the Clinical Credibility Scorecard, a 28-question assessment that helps you identify gaps in your clinical foundation, evidence strategy, safety architecture, and investor readiness, and the Red Flag Detection Checklist, a 25-question assessment that tells you whether your symptom-tracking app can actually detect and act on medical red flags, not just log them.
If you are preparing to pitch, pursuing healthcare partnerships, or simply want to know where your product stands clinically, start here.
Access the toolkit → app.ayomide.me
Thanks for reading. See you soon!
Dr. Ayomide O.
Clinical Strategy & African Market Advisory
Find me on LinkedIn or Book a 1:1 Call
